- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.08. | IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib | ||
| 03.08. | Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy | ||
| 31.07. | Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns | ||
| 31.07. | J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout | ||
| 31.07. | miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies | ||
| 31.07. | Resilience and Lilly to increase US medicines production with $750m investment | ||
| 30.07. | Pfizer seeks label expansion for Litfulo after double Phase III NSV win | ||
| 30.07. | EU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvals | ||
| 30.07. | FDA AdCom shuns Capricor's DMD cell therapy amid data dispute | ||
| 30.07. | The $1.2tn untapped pharma opportunity in tropical conservation | ||
| 30.07. | Amgen's Repatha receives positive CHMP opinion for broader cardiovascular use | ||
| 30.07. | Synlogic and Caldera sign merger agreement | ||
| 29.07. | AdCom expected for uniQure's Huntington's gene therapy, chief medical officer says | ||
| 29.07. | GSK eyes future growth with cost-cutting plan amid promising Q2 | ||
| 29.07. | FDA grants fast track designation for HAYA Therapeutics' HTX-001 | ||
| 29.07. | Eisai and CORE Biomedicine agree on global licence for oncology pipeline | ||
| 28.07. | Leadership changes afoot at two CGT biotechs | ||
| 28.07. | Apnimed scouts $160m IPO to back late-stage sleep apnoea pill development | ||
| 28.07. | BioMarin and n-Lorem partner on early research for ReNU syndrome therapy | ||
| 28.07. | argenx signs agreement to buy Forte Biosciences for $2.2bn | ||
| 27.07. | Outlook Therapeutics wins FDA approval for Lytenava in wet AMD | ||
| 27.07. | Biointron introduces RushData platform for AI-driven antibody discovery | ||
| 27.07. | Kenvue's Tylenol with Naproxen gains FDA approval | ||
| 24.07. | Sanofi abandons eczema drug approval efforts in another blow to OX40 class | ||
| 24.07. | BeOne to invest $300m in US manufacturing facility expansion |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.